BMY vs JNJ
Bristol Myers Squibb Co. and Johnson & Johnson, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BMY | JNJ |
|---|---|---|
| Revenue | $48.2B | $94.2B |
| Net income | $7.1B | $26.8B |
| Gross margin | 71.1% | 67.9% |
| Net margin | 14.6% | 28.5% |
| Return on equity | 40.5% | 35.0% |
| Diluted EPS | $3.46 | $11.03 |
| Dividend / share | $2.49 | $5.14 |
| Payout ratio | 71.5% | · |
| Free cash flow | $12.8B | $19.7B |
| Equity | $18.5B | · |
| Net debt / equity | 1.87× | 0.27× |
| Current ratio | 1.26× | 1.03× |
| Revenue CAGR 5y | 2.5% | 2.7% |
| Profit CAGR 5y | · | 12.7% |
JNJ bills 2.0× the revenue of BMY, and keeps more of each dollar of revenue as profit (28.5% against 14.6%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | BMY | JNJ |
|---|---|---|
| FY2025 | $48.2B | $94.2B |
| FY2024 | $48.3B | $88.8B |
| FY2023 | $45.0B | $85.2B |
| FY2022 | $46.2B | $80.0B |
| FY2021 | $46.4B | $78.7B |
| FY2020 | $42.5B | $82.6B |
| FY2019 | $26.1B | $82.1B |
| FY2018 | $22.6B | $81.6B |
| FY2017 | $20.8B | $76.5B |
| FY2016 | $19.4B | $71.9B |
Bottom line
| Fiscal year | BMY | JNJ |
|---|---|---|
| FY2025 | $7.1B | $26.8B |
| FY2024 | $-8.9B | $14.1B |
| FY2023 | $8.0B | $35.2B |
| FY2022 | $6.3B | $17.9B |
| FY2021 | $7.0B | $20.9B |
| FY2020 | $-9.0B | $14.7B |
| FY2019 | $3.4B | $15.1B |
| FY2018 | $4.9B | $15.3B |
| FY2017 | $1.0B | $1.3B |
| FY2016 | $4.5B | $16.5B |
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$45,999,000,000 | JNJ |
| FY2024 | −$40,521,000,000 | JNJ |
| FY2023 | −$40,153,000,000 | JNJ |
| FY2022 | −$33,831,000,000 | JNJ |
| FY2021 | −$32,355,000,000 | JNJ |
| FY2020 | −$40,066,000,000 | JNJ |
| FY2019 | −$55,914,000,000 | JNJ |
| FY2018 | −$59,020,000,000 | JNJ |
| FY2017 | −$55,674,000,000 | JNJ |
| FY2016 | −$52,463,000,000 | JNJ |
| FY2015 | −$53,514,000,000 | JNJ |
| FY2014 | −$58,452,000,000 | JNJ |
| FY2013 | −$54,927,000,000 | JNJ |
| FY2012 | −$49,603,000,000 | JNJ |
| FY2011 | −$43,786,000,000 | JNJ |
| FY2010 | −$42,103,000,000 | JNJ |
| FY2009 | −$43,089,000,000 | JNJ |
| FY2008 | −$46,032,000,000 | JNJ |
| FY2007 | −$45,478,000,000 | JNJ |
JNJ has reported the higher revenue in every one of these 19 fiscal years. The gap has widened since the earliest year compared.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −13.8 pp | JNJ |
| FY2024 | −34.3 pp | JNJ |
| FY2023 | −23.4 pp | JNJ |
| FY2022 | −8.7 pp | JNJ |
| FY2021 | −11.4 pp | JNJ |
| FY2020 | −39.0 pp | JNJ |
| FY2019 | −5.2 pp | JNJ |
| FY2018 | +3.2 pp | BMY |
| FY2017 | +3.0 pp | BMY |
| FY2016 | +0.2 pp | BMY |
| FY2015 | −12.1 pp | JNJ |
| FY2014 | −9.2 pp | JNJ |
| FY2013 | −3.6 pp | JNJ |
| FY2012 | −1.4 pp | JNJ |
| FY2011 | +9.9 pp | BMY |
| FY2010 | +1.5 pp | BMY |
| FY2009 | +43.3 pp | BMY |
| FY2008 | +14.9 pp | BMY |
| FY2007 | +1.4 pp | BMY |
The higher net margin has changed hands between BMY and JNJ over this period.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's net margin has been more volatile than JNJ's over the 19 comparable fiscal years — 17.1 percentage points of standard deviation against 7.3.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between BMY and JNJ over these 19 fiscal years — BMY led in 8 and JNJ in 11.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's return on equity has been more volatile than JNJ's over the 18 comparable fiscal years — 24.0 percentage points of standard deviation against 8.8.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between BMY and JNJ over these 18 fiscal years — BMY led in 7 and JNJ in 11.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.